BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26645239)

  • 21. Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
    Grøndahl V; Binderup T; Langer SW; Petersen RH; Nielsen K; Kjaer A; Federspiel B; Knigge U
    Lung Cancer; 2019 Jun; 132():141-149. PubMed ID: 31097087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular markers for reinforcement of histological subclassification of neuroendocrine lung tumors.
    Kobayashi Y; Tokuchi Y; Hashimoto T; Hayashi M; Nishimura H; Ishikawa Y; Nakagawa K; Sato Y; Takahashi A; Tsuchiya E
    Cancer Sci; 2004 Apr; 95(4):334-41. PubMed ID: 15072592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression of c-kit and bcl-2 in small cell carcinoma and large cell neuroendocrine carcinoma of the lung.
    LaPoint RJ; Bourne PA; Wang HL; Xu H
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):401-6. PubMed ID: 18091382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
    Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
    Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology.
    Cros J; Théou-Anton N; Gounant V; Nicolle R; Reyes C; Humez S; Hescot S; Thomas de Montpréville V; Guyétant S; Scoazec JY; Guyard A; de Mestier L; Brosseau S; Mordant P; Castier Y; Gentien D; Ruszniewski P; Zalcman G; Couvelard A; Cazes A
    Neuroendocrinology; 2021; 111(1-2):158-169. PubMed ID: 32015233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of the E-cadherin/beta-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids.
    Pelosi G; Scarpa A; Puppa G; Veronesi G; Spaggiari L; Pasini F; Maisonneuve P; Iannucci A; Arrigoni G; Viale G
    Cancer; 2005 Mar; 103(6):1154-64. PubMed ID: 15712207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine.
    Travis WD
    Thorac Surg Clin; 2014 Aug; 24(3):257-66. PubMed ID: 25065926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets.
    Faruki H; Mayhew GM; Fan C; Wilkerson MD; Parker S; Kam-Morgan L; Eisenberg M; Horten B; Hayes DN; Perou CM; Lai-Goldman M
    Arch Pathol Lab Med; 2016 Jun; 140(6):536-42. PubMed ID: 26430809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors in neuroendocrine tumours of the lung: a single-centre experience.
    Filosso PL; Ruffini E; Di Gangi S; Guerrera F; Bora G; Ciccone G; Galassi C; Solidoro P; Lyberis P; Oliaro A; Sandri A
    Eur J Cardiothorac Surg; 2014 Mar; 45(3):521-6; discussion 526. PubMed ID: 24092506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
    George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
    Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Profiling and Clinicopathological Characteristics of Neuroendocrine Tumors of the Lung in East Asian Patients.
    Kim M; Chung YS; Kim KA; Shim HS
    In Vivo; 2020; 34(6):3375-3385. PubMed ID: 33144445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
    Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
    Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
    Suzuki M; Yazawa T; Ota S; Morimoto J; Yoshino I; Yamanaka S; Inayama Y; Kawabata Y; Shimizu Y; Komatsu M; Notohara K; Koda K; Nakatani Y
    Histopathology; 2015 Dec; 67(6):806-16. PubMed ID: 25851923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
    Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
    J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung.
    Coppola D; Clarke M; Landreneau R; Weyant RJ; Cooper D; Yousem SA
    Mod Pathol; 1996 May; 9(5):484-90. PubMed ID: 8733762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
    Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
    BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
    Shimakage M; Kodama K; Kawahara K; Kim CJ; Ikeda Y; Yutsudo M; Inoue H
    Oncol Rep; 2009 Jun; 21(6):1367-72. PubMed ID: 19424611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.